Various ocular side effects can occur during amiodarone treatment: Corneal microdeposits, ocular changes connected with thyroid dysfunction, optic neuritis/optic neuropathy, scotoma, macular degeneration, photosensitivity, corneal degeneration. Very frequently (almost without exception) microdeposits form on the cornea when a sufficient tissue concentration of the medicinal product is reached.
These are generally localised beneath the pupil, asymptomatic and are not in any way a contraindication to continued treatment. They may be accompanied by the perception of coloured rings around dazzling lights or by blurred vision. These corneal microdeposits are made up of complex lipid structures and can be reversed on discontinuation of treatment.
In rare cases, serious optic neuritis/optic neuropathy may occur during amiodarone treatment, causing bilateral blindness and, as a result, discontinuation of treatment (Ref. 1).
Summary and recommendation
Regular ophthalmological examinations, including fundoscopy and slit lamp examinations, are recommended during treatment with amiodarone. If visual acuity gradually declines and the visual field becomes impaired, an ophthalmological examination that includes fundoscopy must be carried out without delay. If optic neuropathy/optic neuritis occur, amiodarone treatment must be discontinued owing to possible progression to bilateral blindness (Ref. 1).
Statutory duty of healthcare professionals to report adverse drug reactions (ADRs)
In Switzerland, healthcare professionals who are authorised to dispense or administer medicinal products are obligated to report severe and/or previously unknown side effects. Reports to Swissmedic can be entered and sent in the Electronic Vigilance Reporting Portal “ElViS”.
> ElViS login
References
[1] Information for healthcare professionals (www.swissmedicinfo-pro.ch)
[2] Fasler K, Traber GL, Jaggi GP, Landau K. Amiodarone-associated Optic Neuropathy-A Clinical Criteria-based Diagnosis?. Neuroophthalmol 2017;42(1):2-10.
Note for marketing authorisation holders
If articles in this section refer to individual cases, these cases are already recorded in the Swiss spontaneous reporting system and have been transmitted to all responsible institutions. We ask affected marketing authorisation holders not to report these cases again (“back report”) to Swissmedic.
Excerpt from the official page. The original is authoritative.